Stockwatch: Pandemic Cuts Deep Into Early Commercial Biotech
Traditional Field Force Dynamics Are Challenged Under COVID-19
Executive Summary
Among big pharma there is a creeping realization that the effects of the coronavirus on revenues and prescriptions may linger. At smaller biotechs, it is patently obvious.